U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration approved enzalutamide for the treatment of patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). At the prespecified interim analysis, a statistically significant improvement in overall survival was demonstrated for patients i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Ning, Yang-Min, Brave, Michael, Maher, V. Ellen, Zhang, Lijun, Tang, Shenghui, Sridhara, Rajeshwari, Kim, Geoffrey, Ibrahim, Amna, Pazdur, Richard
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2015
Teme:
Regulatory Issues: FDA
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4524760/
https://ncbi.nlm.nih.gov/pubmed/26070917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0166
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items